Yann LeCun engagement report
@ylecun - 1.3M followers on X
Measured over 27 original posts from a 30-day window, last computed on August 31, 2026.
Engagement
A typical post picks up 513 interactions against 1.3M followers, an engagement rate of 0.04%. Measured over 27 original posts, its engagement rate beats 57% of 3,758 tracked accounts of a similar size, which puts it in the middle of its size range rather than at either end. Posts are seen about 32K times each, and 1.60% of those impressions turn into an interaction. That is about 2.49% of the follower count, which is the gap between an audience on paper and an audience in a timeline. Posting runs at about 4 posts a day over the last 30 days, with activity on roughly 57% of days. Most posts go out around 13:00 UTC, and Wednesday is the busiest day of the week. Of the 27 posts sampled, 37% carry an image or video and 41% link out. The account's strongest tracked post pulled 33K interactions, about 65x its own typical post. Recurring topics include #restoreacataxcredits, #sundayharangue.
Measured over 27 original posts from a 30-day window, last computed on August 31, 2026. Recurring tags: #restoreacataxcredits, #sundayharangue.
Compared with accounts its own size
Yann LeCun's engagement rate beats 57% of the tracked X accounts closest to it in follower count (3,758 accounts, accounts of similar size (decile 9 of 10)). A percentile is spread evenly by construction, so 50 really is the middle of that group and 90 really is its top tenth.
On engagement per impression rather than per follower it beats 64% of the same group. When those two numbers disagree, the gap is about how far its posts travel rather than how people react to them.
Where this sits in the catalog
At 0.04%, Yann LeCun sits above the 25th percentile of the 36,521 accounts in this comparison. That places it in the below the median band, which runs 0.012% to 0.08%.
Show the percentile table
| Percentile | Engagement rate |
|---|---|
| 10th percentile | 0.002% |
| 25th percentile | 0.012% |
| 50th percentile | 0.08% |
| 75th percentile | 0.434% |
| 90th percentile | 2.10% |
| 99th percentile | 160.7% |
This ruler is the whole measured catalog, not a size-matched group: it shows where the raw rate falls across every account we can measure, all of which are large. For a like-for-like comparison, read the size-band percentile above instead. See how the bands are built
Posting timing
This account posts most often around 13:00 UTC, and Wednesday is its busiest day of the week. The bars below are the catalog-wide pattern, with this account's own busiest slot marked. They do not show how this account performs at each hour: we keep one aggregate per account, not one per hour, so that measurement does not exist in our data.
Show engagement by hour posted, utc as a table
| Hour (UTC) | Vs author median | Posts |
|---|---|---|
| 00:00 UTC | -1% | 50K |
| 01:00 UTC | -2% | 51K |
| 02:00 UTC | -3% | 50K |
| 03:00 UTC | -4% | 53K |
| 04:00 UTC | -6% | 43K |
| 05:00 UTC | -4% | 42K |
| 06:00 UTC | -4% | 48K |
| 07:00 UTC | -5% | 52K |
| 08:00 UTC | -4% | 60K |
| 09:00 UTC | -3% | 69K |
| 10:00 UTC | -2% | 72K |
| 11:00 UTC | -3% | 78K |
| 12:00 UTC | -2% | 86K |
| 13:00 UTC | -2% | 94K |
| 14:00 UTC | -4% | 97K |
| 15:00 UTC | -2% | 100K |
| 16:00 UTC | -3% | 97K |
| 17:00 UTC | -2% | 90K |
| 18:00 UTC | -1% | 84K |
| 19:00 UTC | -2% | 79K |
| 20:00 UTC | -1% | 74K |
| 21:00 UTC | -1% | 66K |
| 22:00 UTC | -2% | 57K |
| 23:00 UTC | -2% | 51K |
Show engagement by day of week as a table
| Day | Vs author median | Posts |
|---|---|---|
| Sunday | +4% | 230K |
| Monday | 0% | 286K |
| Tuesday | -2% | 276K |
| Wednesday | -1% | 251K |
| Thursday | -1% | 244K |
| Friday | -3% | 252K |
| Saturday | +3% | 227K |
Best tweets
- Aug 15, 202665x their median
Giving birth in Europe vs in America 😂 https://t.co/oS7w1ia01j
- Aug 19, 202618x their median
Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma. Read more:
- Aug 22, 202617x their median
1/ I'm a cardiologist. I've practiced for twenty-five years, through a lot of "breakthroughs" that turned out to be press releases. So understand the weight of what I'm about to say: I have never seen a single week in medicine like the one we just lived through. In the span of a few days, four separate scientific breakthroughs landed. The stock market treated them as four unrelated stories and sent a handful of biotech companies soaring. But that's the shallow read. Look closer and they are not four stories at all. They are four faces of the same story — the biggest shift in medicine since the discovery of antibiotics. Medicine is becoming programmable. Individualized. Written for one human being instead of the average of millions. Let me walk you through exactly what happened, in plain language, and show you where this is actually headed. Because the future arrived quietly this week, and most people scrolled right past it.
- Aug 14, 202616x their median
What's wrong with Trump's $1B White House reno? Four biggies. 1) He lied that taxpayers wouldn't be on the hook for it. 2) Trump asked Congress to fund it. Congress declined; Trump is doing it anyway. 3) Trump is robbing other pots of money, including for the Secret Service and Nat'l Parks, to do it again, in defiance of Congress 4) Trump is soliciting money from unknown donors for unknown amounts, opening the door to corruption and influence peddling. So, yes, this is much worse than a home reno gone wrong! It's a massive separation of powers issue, and Congress ought to make clear NO FUNDING means NO FUNDING. https://t.co/yXpKCvRT5O
- Aug 18, 202611x their median
Kim Jung Un is the leader of a communist dictatorship. Trump embraces this communist as a friend. Trump also advocates government ownership in private companies. Yet, somehow, Trump supporters want you to believe that “Medicare for all” is the real communist threat. Absurd.
- Aug 20, 20268.2x their median
The newer generation cancer vaccines aren't like the HPV shot (that prevents a virus). These are therapeutic, they treat cancer you already have. And 2026 is the year they stopped being sci-fi. The idea: after surgery, sequence your specific tumor, find the mutations unique to it, and build a custom mRNA vaccine that trains your immune system to hunt any cell carrying them. A wanted poster for your personal cancer. Where we actually are: Melanoma: just like in immunotherapy 15 years ago the furthest along. The press release of positive Phase 3 made the headlines yesterday, the first ever for a personalized cancer vaccine. Earlier data: ~49% lower risk of recurrence. Heading to regulators. Pancreatic cancer: arguably the most stunning. In an early trial, patients whose immune systems responded to the vaccine were far more likely to be alive 6 years later, in a cancer where 5-year survival is barely better than 10 %. Now in a larger trial. Kidney, lung, bladder, brain: all in trials, mostly early phase. The honest caveats: these work best after surgery to stop recurrence, not to melt large tumors. They're personalized, so they might cost $100–300k and take weeks to build per patient. And most are still early-phase. First approvals at best 2027. But the direction is unmistakable. The mRNA platform some parts of the internet spent years calling poison - because they got fooled by bad actors making money on their lies - is turning into the most personalized cancer medicine ever made. These are the main trials currently running:
- Aug 21, 20267.4x their median
President Trump promised there'd be no cuts to Medicaid. Then he pushed through his One Big Beautiful Bill, which cut Medicaid by nearly $1 trillion and has already caused over 5 million Americans to lose health insurance. Read my take in @nytopinion: https://t.co/aoWJDeQ1Kc https://t.co/DJeO2AkY2F
- Nov 29, 20246.3x their median
I do not write posts on X. I tweet links to posts on other platforms. I like and retweet (occasionally) I comment on friends' tweets (rarely) Follow me on...⬇️⬇️⬇️
- Aug 22, 20264.6x their median
I’m a scientist. Every time I hit “post,” I hesitate. Not because I doubt the science. But because I know what’s coming. I know someone will call me a shill. Someone will tell me I’ve been bought by industry. Someone will explain my own field to me after watching a 90-second video. Someone will demand a source, then reject the source because they don’t like who funded it. And someone will confidently tell thousands of people that I’m lying. That is the strange reality of communicating science online. You spend years learning how uncertain science can be. Then you enter a world where the most confident person in the comments often knows the least. But I keep hitting “post.” Because if scientists decide that communicating science isn’t worth the abuse, the people with the least hesitation get to explain science instead. And that seems far more dangerous.
- Aug 21, 20264.4x their median
In 2024, Trump claimed to have “a concept of a plan” to replace Obamacare and bring down health insurance costs. No plan was ever enacted, but he still sabotaged Obamacare. Now millions of Americans are paying thousands more on premiums every year. My final @nytopinion Chart: https://t.co/MbaCP4s5Ez
Ranked by total interactions across everything we have tracked for this account, which is a longer history than the 30-day window the rates above use. The multiple compares each post to this account's own median.
Recurring topics
The most frequent hashtags in the sampled posts. They describe what this account writes about; they are not a performance signal, and the catalog-wide breakdown on the hub shows how little hashtag count moves.
Buy or sell X accounts - escrow-protected
PlayerSells is an escrow marketplace for X accounts. Every deal is protected, with no middleman risk.
Reading these numbers
A typical post picks up 513 interactions against 1.3M followers, an engagement rate of 0.04%. Measured over 27 original posts, its engagement rate beats 57% of 3,758 tracked accounts of a similar size, which puts it in the middle of its size range rather than at either end. Posts are seen about 32K times each, and 1.60% of those impressions turn into an interaction. That is about 2.49% of the follower count, which is the gap between an audience on paper and an audience in a timeline. Posting runs at about 4 posts a day over the last 30 days, with activity on roughly 57% of days. Most posts go out around 13:00 UTC, and Wednesday is the busiest day of the week. Of the 27 posts sampled, 37% carry an image or video and 41% link out. The account's strongest tracked post pulled 33K interactions, about 65x its own typical post. Recurring topics include #restoreacataxcredits, #sundayharangue.
- What is Yann LeCun's engagement rate on X?
- Yann LeCun (@ylecun) has an engagement rate of 0.04%, based on the median interactions across 27 original posts from the last 30 days against 1,285,927 followers. Replies, reposts and quote-posts of other people are excluded from that sample.
- Is that a good engagement rate?
- At 0.04%, Yann LeCun sits above the 25th percentile of the 36,521 accounts in this comparison. Those comparison accounts are all large ones, because our scanning cadence is weighted towards big accounts, so this is a ranking among peers of similar scale rather than a ranking across X.
- Does @ylecun have real engagement?
- Its engagement rate beats 57% of the tracked X accounts closest to it in follower count (3,758 accounts), which puts it in the middle of its size range group. Ranking inside a size band matters because engagement rate falls as accounts grow, so a raw rate would mostly re-measure the follower count. It is a starting point for a look at follower quality, not a verdict on it.
- When does @ylecun post?
- Most posts go out around 13:00 UTC, and Wednesday is its busiest day, at roughly 4.03 posts per day across the measured window.